DBV Tech Announces BLA Filing for VIASKIN(R) Peanut Patch
DBV Technologies submitted a Biologics License Application to the FDA for the peanut patch in children aged 4-7, supported by Phase 3 data. This regulatory milestone marks progress toward a commercial launch for the food allergy treatment.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed